Current Peptide Compliance

The FDA’s list of bulk drug substances that can be used in compounding by 503B outsourcing facilities — commonly known as the “503B Bulks List” — directly determines which peptides can be legally compounded at scale. Understanding this list and its nomination process is essential for any outsourcing facility in the peptide space.

How the Bulks List Works

Under Section 503B of the FDCA, outsourcing facilities may only use bulk drug substances that appear on one of three lists: substances for which there is a USP or NF monograph, substances that appear on the FDA’s published 503B Bulks List, or substances that are components of FDA-approved drugs. For many peptide APIs, the 503B Bulks List is the critical pathway, as not all peptides have USP monographs or appear in approved drug formulations.

The Nomination Process

Any person can nominate a bulk drug substance for inclusion on the 503B list. The nomination must include a description of the substance, its intended use, a summary of available safety and efficacy data, and a rationale for why the substance should be available for compounding. The FDA evaluates nominations based on clinical need, safety profile, and whether adequate data supports the substance’s use in compounded preparations.

Strategic Implications

For peptide compounders, the bulks list creates both opportunities and constraints. Substances on the list can be compounded with greater regulatory certainty, while substances not on the list carry significant legal risk. Companies should monitor FDA rulemaking around the bulks list, participate in public comment periods when relevant peptides are under review, and maintain documentation demonstrating that every substance they compound has a clear legal basis for use.

Need help with 503B regulatory strategy? Current Peptide Compliance provides guidance on bulks list compliance and outsourcing facility requirements. Contact us.